biostudies-literatureKim JSSara and Alex Othon Research FundJerome L. Greene FoundationRheumatology Research FoundationChresanthe Staurulakis Memorial FundJohns Hopkins inHealth initiativeManugian Family ScholarScleroderma Research FoundationNancy and Joachim Bechtle Precision Medicine Fund for SclerodermaNIAMS NIH HHSDonald B. and Dorothy L. Stabler Foundatione70450https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904757biostudies-literatureUnknown45(3-5)<h4>Background</h4>Scleroderma (systemic sclerosis; SSc) is a chronic autoimmune disease known for wide heterogeneity in patients' disease progression in multiple organ systems. Our goal is to guide clinical care by real-time classification of patients into clinically interpretable subpopulations based on their baseline characteristics and the temporal patterns of their disease progression.<h4>Methods</h4>A Bayesian multivariate growth mixture model was fit to identify subgroups of patients from the Johns Hopkins Scleroderma Center Research Registry who share similar lung function trajectories. We jointly modeled forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) as pulmonary outcomes for 289 patients with SSc and anti-topoisomerase 1 antibodies and developed a fStatistics in medicineProbabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings-A Scleroderma Example.PMC12904757R01AR073208K24AR080217P30AR070254Zeger SLWallwork RSShah AAHummers LKKim JSXu YfalseProbabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings-A Scleroderma Example.<h4>Background</h4>Scleroderma (systemic sclerosis; SSc) is a chronic autoimmune disease known for wide heterogeneity in patients' disease progression in multiple organ systems. Our goal is to guide clinical care by real-time classification of patients into clinically interpretable subpopulations based on their baseline characteristics and the temporal patterns of their disease progression.<h4>Methods</h4>A Bayesian multivariate growth mixture model was fit to identify subgroups of patients from the Johns Hopkins Scleroderma Center Research Registry who share similar lung function trajectories. We jointly modeled forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) as pulmonary outcomes for 289 patients with SSc and anti-topoisomerase 1 antibodies and developed a f2026-01-01T00:00:00Z2026 Feb2026-07-15T15:42:57.28Z2026-07-06T03:12:14.684ZS-EPMC129047574168816610.1002/sim.70450